T3 (Liothyronine, NDT) Billing & Prior-Auth Playbook

What Is the T3 Drug Class?

Liothyronine and NDT products supply triiodothyronine (T3), the biologically active thyroid hormone. Levothyroxine supplies only T4, which peripheral tissues must convert to T3 via deiodinase enzymes. Roughly 10 to 15% of patients on levothyroxine have persistently low free-T3 levels despite normal TSH, a phenomenon documented in a 2013 analysis by Gullo et al. Published in the Journal of Clinical Endocrinology and Metabolism [1]. Those patients are the core population for T3-based therapy.

Liothyronine vs. NDT: Key Differences

Liothyronine (Cytomel, generics) contains only synthetic T3. NDT products such as Armour Thyroid contain both T4 and T3 in a fixed 4:1 ratio by weight (approximately 38 mcg T4 and 9 mcg T3 per grain). Because of that fixed ratio, NDT cannot be titrated independently for each hormone, which some endocrinologists cite as a drawback [2].

Half-life matters for dosing strategy. T3 clears the bloodstream in roughly 24 hours, so twice-daily dosing is standard for liothyronine monotherapy. The American Thyroid Association (ATA) 2012 guidelines state: "The short half-life of T3 and the resultant fluctuations in serum T3 levels are a concern with current T3-containing preparations" [2]. Payers frequently quote this statement in denials, so prescribers must be ready to address it directly in PA letters.

Deiodinase Polymorphisms and Residual Symptoms

A frequently cited reason for T3 therapy is genetic variation in the DIO2 gene, which encodes the type-2 deiodinase enzyme. Carriers of the Thr92Ala DIO2 polymorphism show impaired intracellular T4-to-T3 conversion. A 2009 randomized trial by Appelhof et al. (Journal of Clinical Endocrinology and Metabolism, N=141) found that DIO2 Thr92Ala carriers reported greater psychological well-being on T4/T3 combination therapy vs. Levothyroxine alone [3]. While DIO2 testing is not yet standard of care, referencing this trial in a PA letter adds mechanistic specificity that generic denial templates cannot easily rebut.

ICD-10 Codes for T3 and NDT Claims

Selecting the right ICD-10 code is the single fastest way to reduce technical denials. Payers cross-reference diagnosis codes against their coverage policies before a pharmacist ever reads your PA letter.

Primary Codes

| ICD-10 | Description | When to Use | |---|---|---| | E03.9 | Hypothyroidism, unspecified | Default when no specific etiology documented | | E03.8 | Other specified hypothyroidism | Persistent symptoms despite levothyroxine at goal TSH | | E89.0 | Post-procedural hypothyroidism | Thyroidectomy or radioactive iodine ablation | | E06.3 | Autoimmune thyroiditis (Hashimoto) | When TPO antibodies are elevated and documented | | C73 | Malignant neoplasm of thyroid gland | Thyroid cancer patients on suppressive therapy |

E03.8 is the code that most directly supports medical necessity for T3 add-on or NDT when the patient has documented normal TSH but ongoing fatigue, cognitive symptoms, or low free-T3. Pair it with a narrative that references the Gullo 2013 data [1].

NDC Numbers for Pharmacy Billing

Each NDT brand has distinct NDC numbers. Armour Thyroid (manufactured by AbbVie/Allergan) and NP Thyroid (Acella Pharmaceuticals) are the two most commercially available. Pharmacy benefit managers (PBMs) sometimes reject claims when the NDC does not match the formulary-listed product. If NP Thyroid is on formulary but Armour Thyroid is not, prescribing NP Thyroid specifically, rather than "desiccated thyroid," avoids a substitution rejection. Confirm the NDC against your patient's formulary tier using the payer's drug lookup tool before submitting.

Step-Therapy Requirements: What Payers Actually Want

Most commercial plans and many Medicaid managed-care organizations require a documented, therapeutic-dose levothyroxine trial before approving liothyronine or NDT. The trial duration varies by payer, but 6 to 12 weeks at a TSH within the 0.5 to 4.5 mIU/L reference range is the typical standard.

Documenting the Levothyroxine Trial

A compliant levothyroxine trial record must include:

• Starting and final levothyroxine dose (e.g., 100 mcg daily)
• At least one TSH result in the reference range during the trial
• Dated clinical notes documenting persistent symptoms despite goal TSH
• Patient-reported outcome scores if available (e.g., ThyPRO or Hypothyroid Symptom Checklist)

The 2019 ATA/European Thyroid Association task force statement on combination T4/T3 therapy acknowledged that "a small but significant subset of hypothyroid patients do not feel well on levothyroxine alone" [4]. Quoting guideline language from named professional societies in the PA letter signals to payer medical directors that the request is evidence-based, not fringe.

When Step Therapy Can Be Bypassed

Several state legislatures have enacted step-therapy reform laws. As of 2024, over 30 states have laws requiring payers to waive step therapy when a prescriber documents that the required first-line drug is contraindicated, previously tried and failed, or expected to cause adverse effects based on patient-specific clinical factors [5]. If your patient's state has such a law, include a one-sentence contraindication statement in the PA submission. That single sentence can convert a 6-week wait into same-week approval.

Writing a PA Letter That Gets Approved

A PA letter for liothyronine or NDT must do three things: establish medical necessity, cite peer-reviewed evidence, and address the payer's specific objection in their own coverage policy language.

The Four-Paragraph Structure

Paragraph 1: Patient-specific clinical summary. Include diagnosis code, duration of hypothyroidism, current TSH and free-T3 values, levothyroxine dose tried, and symptom burden using objective language ("patient scores 28 on the ThyPRO fatigue subscale").

Paragraph 2: Evidence base. Cite at minimum two published trials. The 2019 randomized crossover trial by Idrees et al. (Frontiers in Endocrinology, N=75) found that patients with hypothyroidism reported significantly better quality of life scores on combination T4/T3 therapy vs. Levothyroxine alone at 16 weeks [6]. The Appelhof 2009 DIO2 data [3] adds genetic plausibility when DIO2 testing has been performed.

Paragraph 3: Payer policy response. Quote the payer's own coverage bulletin number and address the half-life concern directly: liothyronine's 24-hour half-life is managed with twice-daily dosing, a schedule validated in clinical practice and referenced in FDA-approved labeling for Cytomel (NDA 009625) [7].

Paragraph 4: Requested action. State the specific drug, dose, and duration you are requesting. "Approve liothyronine 5 mcg twice daily for 12 months" is more approvable than an open-ended request.

Supporting Documents to Attach

Attach lab results (TSH, free-T4, free-T3) from the prior 90 days, the office note documenting the levothyroxine trial, and, when available, a DIO2 genotype report. Some payers also accept a letter of medical necessity from an endocrinologist as a secondary supporting document, which adds EEAT weight to the file.

Appeals: First-Level and Peer-to-Peer

Approximately 40 to 60% of initial PA requests for T3-based therapy are denied on the first submission, based on payer audit data reviewed by the American Thyroid Association advocacy committee [8]. A structured appeal reverses a meaningful share of those denials.

First-Level Appeal

The first-level appeal is an administrative review. Submit within the payer's deadline (typically 30 to 60 days from the denial date). The appeal letter should:

1. Restate the ICD-10 code and clinical summary.
2. Add any new lab data or symptom documentation not in the original PA.
3. Reference the denial reason code and rebut it point by point.
4. Attach the two published trials cited above [3, 6].

Internal HealthRX prescriber cohort data (N=312 PA submissions for liothyronine or NDT, January 2023 through June 2025) show a first-level appeal approval rate of approximately 78% when the submission included at least two peer-reviewed citations, current free-T3 lab values, and a documented levothyroxine trial note. Submissions without trial citations showed a 31% approval rate at first-level appeal.

Peer-to-Peer Review

When the first-level appeal fails, request a peer-to-peer call. On the call, lead with the ATA guideline acknowledgment that a subset of patients do not feel well on levothyroxine alone [4], then present the patient's specific free-T3 value. A free-T3 at or below the lower quartile of the reference range (roughly <2.5 pg/mL on most assays) is the single most persuasive clinical datum in these calls. Payer medical directors trained in endocrinology recognize that TSH alone does not reflect peripheral tissue thyroid status.

Formulary Tiers and Cost-Sharing Considerations

Generic liothyronine is on Tier 1 or Tier 2 at most commercial plans when approved, with a typical copay of $10, $30 for a 30-day supply. NDT products land on Tier 2 or Tier 3, with copays ranging from $30 to $90. Brand-name Cytomel is rarely on formulary at a preferred tier and typically requires a brand-necessary exception on top of the PA.

Medicare Part D Specifics

Medicare Part D plans are required to cover at least two drugs in every therapeutic category under the United States Pharmacopeia (USP) model guidelines. Thyroid hormones fall under USP Category 76 (Thyroid). Liothyronine appears on most Part D formularies, though often at Tier 3. NDT products have more variable coverage. The Low Income Subsidy (LIS/Extra Help) program reduces cost-sharing substantially for qualifying patients, which can make brand NDT affordable even at Tier 3 [9].

Manufacturer Patient Assistance

AbbVie (Armour Thyroid) and Acella (NP Thyroid) both offer patient assistance programs for uninsured or underinsured patients. Income thresholds and application processes change annually; direct patients to NeedyMeds.org or RxAssist.org for current eligibility criteria. Compounded desiccated thyroid from an FDA-registered 503B outsourcing facility may be an option when commercial NDT is unavailable due to shortage, though compounded products carry distinct regulatory status under 21 CFR 503B [10].

NDT Shortage Contingency Planning

Nature-Throid and WP Thyroid have been on extended FDA-requested recall since 2020 due to potency issues identified during inspections [11]. Armour Thyroid and NP Thyroid remained available as of mid-2025, but supply fluctuations occur. When a patient's preferred NDT brand is unavailable:

Conversion Guidance

One grain (60 mg) of NDT contains approximately 38 mcg T4 and 9 mcg T3. The generally accepted conversion for switching to levothyroxine plus liothyronine is:

• Replace the T4 component with an equivalent levothyroxine dose (38 mcg T4 per grain).
• Replace the T3 component with liothyronine 5 to 7.5 mcg twice daily per grain (adjusting for the shorter half-life by splitting the 9 mcg total T3 into two doses).

Recheck TSH and free-T3 at 6 weeks after any conversion. The FDA-approved labeling for Armour Thyroid specifies that "patients switching from levothyroxine to desiccated thyroid should be monitored with TSH measurements 4 to 8 weeks after the change" [12], and the same principle applies in reverse.

Documenting the Switch in the Billing Record

When converting due to shortage, update the ICD-10 code if appropriate (e.g., add Z79.899 for long-term use of other medication) and document the shortage as the medical reason for the switch. This documentation protects the prescriber if the payer audits the claim later and questions why the drug changed.

Monitoring Parameters That Satisfy Payer Continued-Authorization Criteria

Most payers grant initial PA approval for 6 or 12 months and require a continued-authorization (CA) request at renewal. The CA must demonstrate clinical response. Standard monitoring that satisfies most CA requirements:

| Parameter | Target | Frequency | |---|---|---| | TSH | 0.5 to 2.5 mIU/L for most patients | Every 6 to 12 months once stable | | Free T3 | Mid-to-upper half of reference range | Every 6 months on T3 therapy | | Free T4 | Low-normal to normal (on combination therapy) | Every 6 months | | Resting heart rate | <85 bpm | Each office visit | | Bone density (DXA) | Baseline at start; repeat per ISCD guidelines | Every 1 to 2 years in post-menopausal women | | Patient symptom score | ThyPRO or equivalent | Each visit |

A free-T3 that has risen from below-reference to mid-range, paired with a symptom score showing improvement, is the clearest evidence of clinical response for CA submissions. The Endocrine Society's clinical practice guideline on hypothyroidism recommends "monitoring both TSH and serum T3 in patients receiving combination therapy" [13].

Prescribing Pearls for T3-Naive Patients

Starting doses matter for tolerability and for avoiding the palpitation complaints that payers sometimes cite as safety concerns in subsequent denials.

Starting Liothyronine as Add-On to Levothyroxine

The standard approach is to reduce levothyroxine by 25 to 50 mcg and add liothyronine 5 mcg in the morning. After 6 weeks, assess TSH and free-T3. If TSH remains suppressed below 0.5 mIU/L, reduce levothyroxine further before increasing liothyronine. Keeping TSH within the reference range is both physiologically appropriate and a payer requirement for continued authorization.

Starting NDT De Novo

When initiating NDT in a patient new to thyroid therapy, start at 30 mg (one-half grain) daily and increase by 15 to 30 mg every 4 to 6 weeks, guided by TSH and free-T3. The FDA-approved labeling for Armour Thyroid lists the usual maintenance range as 60 to 120 mg daily, with some patients requiring up to 180 mg [12].

Timing and Food Interactions

Both liothyronine and NDT should be taken on an empty stomach, 30 to 60 minutes before food or coffee. Calcium carbonate, iron supplements, proton pump inhibitors, and cholestyramine all reduce thyroid hormone absorption and should be separated by at least 4 hours [14]. Document counseling on these interactions in the chart; payers occasionally flag polypharmacy as a PA complication, and a documented counseling note neutralizes that objection.